BIG
TRDA icon

Brooklyn Investment Group’s Entrada Therapeutics TRDA Stock Holding History

Brooklyn Investment Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-393
Closed -$2.64K – 2519
2025
Q2 		$2.64K Buy
+393
New +$3.16K ﹤0.01% 2692

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Brooklyn Investment Group's TRDA Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 393 shares — an estimated $2.64K sold.

Brooklyn Investment Group first reported a position in TRDA in Q2 2025 and held it in 1 quarter. The position peaked at $2.64K in Q2 2025. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 393 Entrada Therapeutics shares in Q3 2025, an estimated $2.64K.
  • Brooklyn Investment Group first reported a position in Entrada Therapeutics in Q2 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Entrada Therapeutics position peaked at $2.64K in Q2 2025.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.